Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
about
Turning the tide in myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.Survival of pancreatic cancer cells lacking KRAS function.Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.Wild-type Kras expands and exhausts hematopoietic stem cells.
P2860
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
@en
type
label
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
@en
prefLabel
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
@en
P2093
P2860
P356
P1433
P1476
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
@en
P2093
B S Slusher
C L Cottonham
J Akutagawa
L S Friedman
M Quirindongo-Crespo
P2860
P2888
P304
P356
10.1038/LEU.2016.14
P577
2016-02-12T00:00:00Z